Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation
Kanqiu Jiang,* Mingjing Shen,* Weihua Xu Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou Shi, Jiangsu Sheng, People’s Republic of China *These authors contributed equally to this work Purpose: In this study, a novel arginine, glycine, a...
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Dove Medical Press
2018-04-01
|
| Sarja: | International Journal of Nanomedicine |
| Aiheet: | |
| Linkit: | https://www.dovepress.com/arginine-glycine-aspartic-acid-peptide-modified-paclitaxel-and-curcumi-peer-reviewed-article-IJN |
| _version_ | 1830286747185971200 |
|---|---|
| author | Jiang K Shen M Xu W |
| author_facet | Jiang K Shen M Xu W |
| author_sort | Jiang K |
| collection | DOAJ |
| description | Kanqiu Jiang,* Mingjing Shen,* Weihua Xu Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou Shi, Jiangsu Sheng, People’s Republic of China *These authors contributed equally to this work Purpose: In this study, a novel arginine, glycine, aspartic acid peptide (RGD)-modified paclitaxel and curcumin co-loaded liposomes were developed to evaluate their antitumor activity in vitro and in vivo. Materials and methods: Co-loaded liposomes were prepared using the solvent evaporation method. The particles had spherical shapes under electron microscopy with sizes <130 nm. Results: By comparison with the free drug, RGD-modified paclitaxel and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes have sustained-release properties in vitro. In vivo, there was no significant difference in pharmacokinetic parameters between the RGD-modified paclitaxel and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes. A strong green fluorescence was observed in the cytoplasmic region after incubation of RGD-modified paclitaxel and curcumin co-loaded liposomes for 2 h. RGD-modified paclitaxel and curcumin co-loaded liposomes showed a superior antiproliferative effect on A549 cells with a possible mechanism that suppressed the multidrug resistance phenomenon and exhibited a clear synergistic effect. Conclusion: The results indicate that RGD-modified paclitaxel and curcumin co-loaded liposomes had a better antitumor effect in vivo than the non-modified LPs. These results indicate that RGD-modified co-loaded liposomes are a promising candidate for antitumor drug delivery. Keywords: arginine, glycine, aspartic acid peptide, paclitaxel, curcumin, liposome, cell uptake, cytotoxicity study, in vivo anti-tumor study |
| first_indexed | 2024-12-19T04:05:13Z |
| format | Article |
| id | doaj.art-dbb63c5e22f3429ca2ab4669dba9b41f |
| institution | Directory Open Access Journal |
| issn | 1178-2013 |
| language | English |
| last_indexed | 2024-12-19T04:05:13Z |
| publishDate | 2018-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nanomedicine |
| spelling | doaj.art-dbb63c5e22f3429ca2ab4669dba9b41f2022-12-21T20:36:33ZengDove Medical PressInternational Journal of Nanomedicine1178-20132018-04-01Volume 132561256938009Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluationJiang KShen MXu WKanqiu Jiang,* Mingjing Shen,* Weihua Xu Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou Shi, Jiangsu Sheng, People’s Republic of China *These authors contributed equally to this work Purpose: In this study, a novel arginine, glycine, aspartic acid peptide (RGD)-modified paclitaxel and curcumin co-loaded liposomes were developed to evaluate their antitumor activity in vitro and in vivo. Materials and methods: Co-loaded liposomes were prepared using the solvent evaporation method. The particles had spherical shapes under electron microscopy with sizes <130 nm. Results: By comparison with the free drug, RGD-modified paclitaxel and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes have sustained-release properties in vitro. In vivo, there was no significant difference in pharmacokinetic parameters between the RGD-modified paclitaxel and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes. A strong green fluorescence was observed in the cytoplasmic region after incubation of RGD-modified paclitaxel and curcumin co-loaded liposomes for 2 h. RGD-modified paclitaxel and curcumin co-loaded liposomes showed a superior antiproliferative effect on A549 cells with a possible mechanism that suppressed the multidrug resistance phenomenon and exhibited a clear synergistic effect. Conclusion: The results indicate that RGD-modified paclitaxel and curcumin co-loaded liposomes had a better antitumor effect in vivo than the non-modified LPs. These results indicate that RGD-modified co-loaded liposomes are a promising candidate for antitumor drug delivery. Keywords: arginine, glycine, aspartic acid peptide, paclitaxel, curcumin, liposome, cell uptake, cytotoxicity study, in vivo anti-tumor studyhttps://www.dovepress.com/arginine-glycine-aspartic-acid-peptide-modified-paclitaxel-and-curcumi-peer-reviewed-article-IJNRGDPaclitaxelCurcuminliposomeCell uptakeCytotoxicity studyIn vivo anti-tumor study |
| spellingShingle | Jiang K Shen M Xu W Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation International Journal of Nanomedicine RGD Paclitaxel Curcumin liposome Cell uptake Cytotoxicity study In vivo anti-tumor study |
| title | Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation |
| title_full | Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation |
| title_fullStr | Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation |
| title_full_unstemmed | Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation |
| title_short | Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation |
| title_sort | arginine glycine aspartic acid peptide modified paclitaxel and curcumin co loaded liposome for the treatment of lung cancer in vitro vivo evaluation |
| topic | RGD Paclitaxel Curcumin liposome Cell uptake Cytotoxicity study In vivo anti-tumor study |
| url | https://www.dovepress.com/arginine-glycine-aspartic-acid-peptide-modified-paclitaxel-and-curcumi-peer-reviewed-article-IJN |
| work_keys_str_mv | AT jiangk arginineglycineasparticacidpeptidemodifiedpaclitaxelandcurcumincoloadedliposomeforthetreatmentoflungcancerinvitrovivoevaluation AT shenm arginineglycineasparticacidpeptidemodifiedpaclitaxelandcurcumincoloadedliposomeforthetreatmentoflungcancerinvitrovivoevaluation AT xuw arginineglycineasparticacidpeptidemodifiedpaclitaxelandcurcumincoloadedliposomeforthetreatmentoflungcancerinvitrovivoevaluation |